20212229

Source:http://linkedlifedata.com/resource/pubmed/id/20212229

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0017636, umls-concept:C0030705, umls-concept:C0205390, umls-concept:C0205420, umls-concept:C1442989, umls-concept:C1518321, umls-concept:C1559154, umls-concept:C1704426
pubmed:issue	3
pubmed:dateCreated	2010-3-9
pubmed:abstractText	To determine the maximum tolerated dose of ABT-510, a thrombospondin-1 mimetic drug with antiangiogenic properties, when used concurrently with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/P50 CA097247
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0372436
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating, http://linkedlifedata.com/resource/pubmed/chemical/Dacarbazine, http://linkedlifedata.com/resource/pubmed/chemical/Fibroblast Growth Factor 1, http://linkedlifedata.com/resource/pubmed/chemical/NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva..., http://linkedlifedata.com/resource/pubmed/chemical/Oligopeptides, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, TIE-1, http://linkedlifedata.com/resource/pubmed/chemical/temozolomide
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	1538-3687
pubmed:author	pubmed-author:Fathallah-ShaykhHassan MHM, pubmed-author:FiveashJohn BJB, pubmed-author:GillespieGeorge YGY, pubmed-author:GladsonCandece LCL, pubmed-author:HuangZhiZ, pubmed-author:JohnsonMartin JMJ, pubmed-author:KekanManasi SMS, pubmed-author:KuoHuichienH, pubmed-author:MarkertJames MJM, pubmed-author:MelethSreelathaS, pubmed-author:NaborsLouis BLB
pubmed:issnType	Electronic
pubmed:volume	67
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	313-9
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:20212229-Adult, pubmed-meshheading:20212229-Aged, pubmed-meshheading:20212229-Antineoplastic Agents, Alkylating, pubmed-meshheading:20212229-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:20212229-Brain Neoplasms, pubmed-meshheading:20212229-Combined Modality Therapy, pubmed-meshheading:20212229-Dacarbazine, pubmed-meshheading:20212229-Disease Progression, pubmed-meshheading:20212229-Dose-Response Relationship, Drug, pubmed-meshheading:20212229-Drug Administration Schedule, pubmed-meshheading:20212229-Female, pubmed-meshheading:20212229-Fibroblast Growth Factor 1, pubmed-meshheading:20212229-Gene Expression Regulation, Neoplastic, pubmed-meshheading:20212229-Glioblastoma, pubmed-meshheading:20212229-Humans, pubmed-meshheading:20212229-Kaplan-Meier Estimate, pubmed-meshheading:20212229-Magnetic Resonance Imaging, pubmed-meshheading:20212229-Male, pubmed-meshheading:20212229-Middle Aged, pubmed-meshheading:20212229-Oligopeptides, pubmed-meshheading:20212229-Receptor, TIE-1, pubmed-meshheading:20212229-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:20212229-Treatment Outcome
pubmed:year	2010
pubmed:articleTitle	A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
pubmed:affiliation	Neuro-oncology Program, University of Alabama at Birmingham, 510 20th St S, FOT 1020, Birmingham, AL 35294, USA. bnabors@uab.edu
pubmed:publicationType	Journal Article, Clinical Trial, Phase I, Research Support, N.I.H., Extramural